• Home
  • About Us
    • About Us
    • Subscribe
    • Privacy Policy
  • Advertise
    • Advertise On IP Watch
    • Editorial Calendar
  • Videos
  • Links
  • Help

Intellectual Property Watch

Original news and analysis on international IP policy

  • Copyright
  • Patents
  • Trademarks
  • Opinions
  • People News
  • Venues
    • Bilateral/Regional Negotiations
    • ITU/ICANN
    • United Nations – other
    • WHO
    • WIPO
    • WTO/TRIPS
    • Africa
    • Asia/Pacific
    • Europe
    • Latin America/Caribbean
    • North America
  • Themes
    • Access to Knowledge/ Open Innovation & Science
    • Food Security/ Agriculture/ Genetic Resources
    • Finance
    • Health & IP
    • Human Rights
    • Internet Governance/ Digital Economy/ Cyberspace
    • Lobbying
    • Technical Cooperation/ Technology Transfer
  • Health Policy Watch

WHO Should Have The Evidence? Ben Goldacre Refutes WHO Director’s Claim

24/05/2013 by Intellectual Property Watch 2 Comments

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

The views expressed in this article are solely those of the authors and are not associated with Intellectual Property Watch. IP-Watch expressly disclaims and refuses any responsibility or liability for the content, style or form of any posts made to this forum, which remain solely the responsibility of their authors.

By Lindsay Gill

“Bad Science” adversary and journalist, Dr Ben Goldacre, this week challenged WHO Director of Ethics and Social Determinants of Health, Dr Rüdiger Krech, on his understanding of published evidence.

Krech, who was speaking about the importance of transparency at the Sixty-Sixth World Health Assembly (WHA) in Geneva, argued that scientific journals do not publish trials that have not been registered on the WHO International Clinical Trials Registry Platform.

When questioned on Twitter about this claim, Ben Goldacre affirmed that journals still publish unregistered trials, tweeting, “Dr Krech is disagreeing with the published evidence.”

In an email to Krech, who welcomed the discussion, Goldacre said, “Current evidence certainly shows poor compliance by journals checking for registration before publication. I think it’s important to recognise that there is a huge amount to be done here.”

Goldacre then called on the WHO to support the AllTrials campaign for governments, regulators and research bodies, to implement measures that would see all past and present clinical trials registered and fully reported.

AllTrials.net estimates that around half of all clinical trials have not been published. Currently, drug companies and researchers may withhold the results of clinical trials from doctors and patients, which can mislead people about the benefits or risks of a treatment. Transparency of clinical results would provide practitioners with more accurate estimates of the effects of interventions and prevent the repetition of costly research.

Addressing 194 member states at the opening of the WHA, WHO Director General Margaret Chan said, “Research, evidence, and information are the foundation for sound health policies, for monitoring the impact, and for ensuring accountability. They keep us on track.”

WHO’s support for the registration and reporting of all clinical trials is a necessity for this to be achieved.

Note: The twitter conversation took place between @SciCommOok and @bengoldacre on 22 May and can be found here.


A graduate with a Bachelor of Science in Biology and Science Communication, and Master of Arts in Journalism and Media, Lindsay Gill has more than nine years experience of communicating scientific research and development to industry, government and the public in the UK. Since 2009, Lindsay has worked as the Science Communication Manager for the Centre for Process Innovation, where she is responsible for the dissemination of collaborative research project activities and protection of related scientific IP. Lindsay has a variety of experience in areas including, online media development, film and radio production, and writing for both print and digital platforms.

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Related

Creative Commons License"WHO Should Have The Evidence? Ben Goldacre Refutes WHO Director’s Claim" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Filed Under: Inside Views, Language, Themes, Venues, Access to Knowledge/ Education, English, Health & IP, Information and Communications Technology/ Broadcasting, Innovation/ R&D, WHO

Trackbacks

  1. Who should respect evidence? | There's an Elephant in the Room says:
    25/05/2013 at 2:02 pm

    […] http://www.ip-watch.org/2013/05/24/who-should-have-the-evidence-ben-goldacre-refutes-who-directors-c… […]

    Reply
  2. Book - Book Review: Bad Science - Kittysneezes says:
    10/07/2013 at 8:23 am

    […] WHO Should Have The Evidence? Ben Goldacre Refutes WHO Director’s Claim […]

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • Vimeo
My Tweets

IPW News Briefs

Saudis Seek Alternative Energy Partners Through WIPO Green Program

Chinese IP Officials Complete Study Of UK, European IP Law

Perspectives on the US

In US, No Remedies For Growing IP Infringements

US IP Law – Big Developments On The Horizon In 2019

More perspectives on the US...

Supported Series: Civil Society And TRIPS Flexibilities

Civil Society And TRIPS Flexibilities Series – Translations Now Available

The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa

Read the TRIPS flexibilities series...

Paid Content

Interview With Peter Vanderheyden, CEO Of Article One Partners

More paid content...

IP Delegates in Geneva

  • IP Delegates in Geneva
  • Guide to Geneva-based Public Health and IP Organisations

All Story Categories

Other Languages

  • Français
  • Español
  • 中文
  • اللغة العربية

Archives

  • Archives
  • Monthly Reporter

Staff Access

  • Writers

Sign up for free news alerts

This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy

Copyright © 2025 · Global Policy Reporting

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.